Truqap is actually a kinase inhibitor that works by blocking pathways that support the cancer cells survive and develop, so cuts down most cancers development. Truqap is from a class of medicines named an AKT inhibitor. Truqap been given FDA approval on November 17, 2023, just after beneficial results in https://6--hydroxy-paclitaxel35790.bloggactif.com/36060468/a-secret-weapon-for-sotorasib